Market Overview

Jefferies Initiating Coverage On DexCom At Buy


According to Jefferies, DexCom (NASDAQ: DXCM) is initiated with a Buy rating.

Jefferies reported that DexCom offers the Seven Plus Sensor to continuously monitor glucose levels, allowing patients to better manage their glucose levels. “Adoption of CGM technology is still in its infancy with the currently indicated population only 3-5% penetrated. DexCom's device is widely considered to be the best of its kind and competes with only one other company, Medtronic, in the CGM space. We use EV/Sales to value DXCM as profitability is still emerging. We use a multiple of 9.0x, a premium to the 7.5x average comparables multiple rolled forward to 2012 sales for a one-year price target of $17.”

DexCom closed yesterday at $6.47.

Posted-In: dexcom JefferiesAnalyst Color Initiation Analyst Ratings


Related Articles (DXCM)

View Comments and Join the Discussion!

Latest Ratings

WDAYSociete GeneraleUpgrades
BKUDA DavidsonInitiates Coverage On39.0
JDVertical GroupInitiates Coverage On
WWells FargoMaintains123.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Goldman Sachs Updates On EBAY-GSI Merger

Lazard Downgrades GSI Commerce To Hold